• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Day 1 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference


Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

To stay informed on conference insights, subscribe to receive our eNewslettters.

What to Expect at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

The inaugural RAVE conference begins today in Chicago, Illinois.

Spotlighting Vitiligo: New Innovations to be Presented at RAVE 2024

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.

A RAVE Upgrade: Previewing Revolutionizing Alopecia Areata, Vitiligo, and Eczema

Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.

Serum CXCL10 Levels Decreased With Use of Ruxolitinib Cream In Patients With Vitiligo

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Considerations for Topical Therapeutics and Clinical Excellence in Vitiligo

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Ritlecitinib Shows Promising Results in Long-Term Trial

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

Upadacitinib Demonstrates Continued Improvements in Patients With Moderate to Severe AD Through 140 Weeks

Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.

Don’t Forget to Address Autoimmune Comorbidities of Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

What’s New in Devices for Vitiligo?

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.